Loading provider…
- Featuresarrow_drop_down
- Solutionsarrow_drop_down
Loading provider…
Your Medical Sales Assistants that help you easily find, convert and close your ideal providersPsychiatry Physician in Orange, CA
NPI: 1174589642Primary Practice Location
Advantage Neuropsychiatric Assoc
1010 W Chapman Ave, Orange, CA
Primary Employer
Advantage Neuropsychiatric Assoc
advantagepsyc.com
HQ Phone
Get M.D. Daniel's Phone NumberMobile
Get M.D. Daniel's MobileLooking to connect with more Physicians?
Dmand AI gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Get Started for Freearrow_outwardCA State Medical License
CA State Medical License
1990 - 2026
American Board of Psychiatry and Neurology
Psychiatry
University of California (Irvine)
Residency • Psychiatry
1989 - 1993
Jacobs School of Medicine and Biomedical Sciences
medicine.buffalo.edu
Medical School
Until 1989
| # | Procedure Code (CPT®/HCPCS II) | Procedure Patients | Procedure Volume |
|---|---|---|---|
| 1 | 99308Subsequent nursing facility care with straightforward level of medical decision making, per day, if using time, at least 15 minutes | 501 | 1,328 |
| 2 | 99306Initial nursing facility visit, typically 45 minutes per day | 413 | 414 |
| 3 | 99232Subsequent hospital inpatient care, typically 25 minutes per day | 243 | 1,701 |
| 4 | 99223Initial hospital inpatient care, typically 70 minutes per day | 147 | 163 |
| 5 | 99348Residence visit for established patient with low level of medical decision making, per day, if using time, at least 30 minutes | 75 | 362 |
Lead Sponsor: Luye Pharma Group Ltd.
Intervention / Treatment: DRUG: LY03010 351 mg treatment group, gluteal, DRUG: LY03010 156 mg treatment group, deltoid, DRUG: LY03010 156 mg treatment group, gluteal, DRUG: LY03010 351 mg treatment group, deltoid
Lead Sponsor: Shire
Intervention / Treatment: DRUG: Placebo, DRUG: SHP465
Lead Sponsor: Luye Pharma Group Ltd.
Intervention / Treatment: DRUG: Risperdal® Consta®, DRUG: LY03004
